ILAPRAZOLE

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C19H18N4O2S
Molecular Weight	366.437
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=C(C)C(C[S+]([O-])C2=NC3=C(N2)C=CC(=C3)N4C=CC=C4)=NC=C1

InChI

InChIKey=HRRXCXABAPSOCP-UHFFFAOYSA-N

InChI=1S/C19H18N4O2S/c1-13-17(20-8-7-18(13)25-2)12-26(24)19-21-15-6-5-14(11-16(15)22-19)23-9-3-4-10-23/h3-11H,12H2,1-2H3,(H,21,22)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11304936 | https://www.ncbi.nlm.nih.gov/pubmed/11215326 | http://www.drugsupdate.com/generic/view/1243 | http://eng.dailypharm.com/News/news_view.html?ID=362 | https://www.ncbi.nlm.nih.gov/pubmed/28388576 | http://www.pharmalink.kr/detailinfo.php?code=20081068801

Ilaprazole or IY-81149 (2-[(4-methoxy-3-methyl)-2-pyridinyl]methylsulfinyl -5-(1H-pyrrol-1-yl)-1H-benzimidazole, CAS 172152-36-2) is a proton pump inhibitor. Ilaprazole revealed the characteristics as a strong proton pump inhibitor, and its potency against gastric acid secretion was superior to that of the reference drug, omeprazole. Ilaprazole is approved in China and South Korea for the treatment of gastroesophageal reflux disorders (GERD), dyspepsia and peptic ulcers. Recently it was discovered that ilaprazole inhibited the cancer growth by targeting T-cell-originated protein kinase (TOPK) both in vitro and in vivo.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sodium/potassium-transporting ATPase 39 Target ID: CHEMBL2095186 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11304936	Inhibitor 8297		6.0 µM [IC50]
PDZ-binding kinase 2 Target ID: CHEMBL4896 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28388576	Inhibitor 8297		111.0 µM [Kd]

Conditions

Condition	Modality	Highest Phase	Product
Colon cancer 62 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28388576	Primary	Preclinical	Unknown Approved Use Unknown
Gastroesophageal reflux disease 59 Sources: http://adisinsight.springer.com/drugs/800010706	Primary	Approved 8429	Noltec Approved Use Ilaprazole is used for the treatment of gastroesophageal reflux disorders (GERD), dyspepsia and peptic ulcers. Launch Date 1.19111038E12
Peptic ulcer 72 Sources: http://adisinsight.springer.com/drugs/800010706	Primary	Approved 8429	Noltec Approved Use Ilaprazole is used for the treatment of gastroesophageal reflux disorders (GERD), dyspepsia and peptic ulcers. Launch Date 1.19111038E12

PubMed

Title	Date	PubMed
Comparison of IY81149 with omeprazole in rat reflux oesophagitis.	2000 Oct-Dec	11350494

Patents

Sample Use Guides

In Vivo Use Guide

Short-term treatment of duodenal ulcer: Normally, 10 mg of adult is administered orally once a day. It is usually administered for up to 4 weeks. Short-term treatment of gastric ulcer: Normally, an adult dose of 10 mg is orally administered once a day. It is usually administered for 4 to 6 weeks. This medicine should be swallowed with water 1 hour before meals and should not be chewed or crushed. The recommended adult dosage of Ilaprazole is 5-20 mg/day.

Route of Administration: Oral

In Vitro Use Guide

Ilaprazole exhibited potent inhibitory activities against the growth of HCT116 cells (IC50 = 40 uM) and ES-2 cells (IC50 = 33.2 uM). Ilaprazole (100 and 50 uM) induces apoptosis in ES-2 and HCT116 cells.

Name

Type

Language

ILAPRAZOLE

Official Name

English

NOLTEC

Brand Name

English

Ilaprazole [WHO-DD]

Common Name

English

IY-81149

Systematic Name

English

ilaprazole [INN]

Common Name

English

2-((RS)-((4-METHOXY-3-METHYLPYRIDIN-2-YL)METHYL)SULFINYL)-5-(1H-PYRROL-1-YL)-1H-BENZIMIDAZOLE

Systematic Name

English

ILAPRAZOLE [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29723